Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Background and Aims Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with co...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of gastroenterology 2015-07, Vol.34 (4), p.286-291
Main Authors: Goyal, Sundeep Kumar, Dixit, Vinod Kumar, Shukla, Suneet Kumar, Ghosh, Jayant, Behera, Manas, Tripathi, Manish, Gupta, Neha, Ranjan, Arttrika, Jain, Ashok Kumar
Format: Article
Language:English
Subjects:
Adult
Aged
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Carcinoma, Hepatocellular - etiology
Carcinoma, Hepatocellular - prevention & control
Female
Follow-Up Studies
Gastroenterology
Guanine - administration & dosage
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatology
Humans
Liver Cirrhosis - drug therapy
Liver Cirrhosis - etiology
Liver Neoplasms - etiology
Liver Neoplasms - prevention & control
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Retrospective Studies
Tenofovir - administration & dosage
Tenofovir - therapeutic use
Time Factors
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with compensated or decompensated cirrhosis. Methods We retrospectively analyzed laboratory and clinical data of 400 HBV-related cirrhotic patients without access to liver transplantation, who were treated with tenofovir/entecavir therapy, from January 2007 to January 2014. Two hundred and ten (52.5 %) patients had at least one of the components of decompensation at baseline. Two hundred and twenty (55 %) and 180 (45 %) patients were initiated tenofovir and entecavir, respectively. Follow up period was 45 (12–68) months for tenofovir and 36 (11–60) months for entecavir. Results At the end of 1 year, levels of HBV DNA
ISSN:0254-8860
0975-0711
DOI:10.1007/s12664-015-0576-1